Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING LLC
Ampronix

Low-Dose CT Screening Study Reveals Improved Diagnostic Performance for Lung Cancer

By Medimaging International staff writers
Posted on 09 Jul 2014
Image: A computed tomography (CT) scan showing lung cancer (Photo courtesy of Kevin Kavanagh, MD).
Image: A computed tomography (CT) scan showing lung cancer (Photo courtesy of Kevin Kavanagh, MD).
Investigators of a new study demonstrated good compliance and patient survival outcomes using a five-year low-dose computed tomography (LDCT) screening protocol in individuals at high-risk of developing lung cancer.

This COSMOS (Continuous Observation of SMOking Subjects) study protocol had fewer patients requiring additional diagnostic follow-up compared to other studies, including the US National Lung Cancer Screening Trial (NLST), with a minimal number of incorrect diagnoses.

The five-year survival rate for early diagnosed lung cancer is 50% but after the cancer has spread to distant regions it is only 4%. Recently, the NLST revealed a 20% lung cancer mortality reduction with LDCT compared to chest X-ray, which verified that early detection can decrease lung cancer deaths. However, few studies have comprehensively assessed the diagnostic performance, invasiveness and side effects of LDCT screening protocols with enduring follow-up.

The COSMOS study screened 5,203 asymptomatic high-risk subjects (age ≥ 50 and ≥ 20 pack years smoking history) who, based on the study criteria, either went on to other diagnostic procedures (CT, positron emission tomography [PET], or surgery) to verify lung cancer, or were rescreened every year for the next four years. All subjects were clinically followed for a median of 5.2 years.

The study’s findings, reported in the July 2014, issue of the Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, show that overall, 79% of the participants remained on the study for five years and only 6.4% required a procedure beyond the yearly LDCT. Primary lung cancer was diagnosed in 175 patients and 78% of these were diagnosed with localized disease. Because of the size and long follow-up, there were 23,116 person-years of observation. Therefore, the overall lung cancer detection rate was 0.76 per 100 person-years.

Out of the 204 invasive diagnostic procedures, 29 were benign for lung cancer, 34 had minor complications, 12 major complications and one postoperative fatality was reported. There were 14 instances where the lesions were not diagnosed as cancer, but were later determined to be cancer on subsequent yearly screening. A high proportion of the cancers (87%) were treated with intent to cure and the overall five-year survival was 78%.

“The results of the COSMOS workup protocol for indeterminate nodules detected with LDCT screening are encouraging, particularly the low recall and delayed diagnosis rates as well as the good long-term survival,” said Dr. Giulia Veronesi, Dr. Giulia Veronesi from the department of thoracic surgery, European Institute of Oncology (Milan, Italy) is a member of the International Association for the Study of Lung Cancer (IASLC), and lead author of the study. “However, the workup can still be improved, possibly by tailoring the screening interval to the risk of the individual being screened using a risk evaluation algorithm that will hopefully also include in the near future molecular markers like a microRNA expression signature in serum.”

Related Links:

European Institute of Oncology



Channels

MRI

view channel
Image: MR Solutions Conversion Kit for MRI Scanner (Photo courtesy of MR Solutions).

Conversion Kit Transforms Clinical MRI System into a Preclinical Scanner

A clinical Magnetic Resonance Imaging (MRI) scanner can now be transformed into an effective preclinical system using a simple conversion kit. The transformation can be carried out in approximately... Read more

Ultrasound

view channel
Image: World’s first 29 MHz micro-ultrasound system (Photo courtesy of Exact Imaging).

Breakthrough High-Resolution Micro-Ultrasound Platform for the Prostate Revealed at AUA 2015

A novel micro-ultrasound imaging platform has been introduced at the annual meeting of the American Urological Association (AUA) 2015 (New Orleans, LA, USA). The probe operates at 29 MHz, and enables... Read more

Nuclear medicine

view channel

Human Prostate Cancer Study Evaluates New Imaging Biomarker

The results of the first human prostate cancer study intended to evaluate a 2nd generation fluorine-18 labeled small-molecule PSMA inhibitor, have been published in the April 28, 2015, issue of the Journal of Molecular Imaging and Biology. The results of the evaluation demonstrated the initial safety, bio-distribution,... Read more

General/Advanced Imaging

view channel

Global Healthcare Study of Coronary Artery Disease Reaches Significant Milestone

A major milestone has been reached in the Lipid-Rich Plaque (LRP) study, a prospective, multicenter clinical trial with the potential to reveal breakthrough correlations between Lipid-Rich Plaques and occurrence of heart attacks. The LPR study has now enrolled 1,000 patients, and aims to identify a correlation between... Read more

Imaging IT

view channel
Image: Carestream Vue Motion Viewer (Photo courtesy of Carestream Healthcare).

New Software Solution Facilitates Secure Data Aggregation from Existing Hospital IT Systems

A medical imaging systems and Information Technology (IT) solutions provider has demonstrated how its advanced healthcare IT software solutions can facilitate high-quality imaging access, and improved... Read more

Industry News

view channel

Advanced Medical Imaging Startup Company Receives Venture Funding

Zebra Medical Vision (Kibbutz Shfayim, Israel) has received an USD 8 million investment from Khosla Ventures (Menlo Park, CA, USA) to double its team, set up headquarters in the US and increase its scope of work to integrate data from additional Health Maintenance Organizations (HMO). Zebra Medical has already partnered... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.